News
Pharmaceutical Technology on MSN1d
BeOne Medicines’ BTK degrader gains EMA PRIME designation
The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.
today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to the Company’s investigational Bruton’s tyrosine kinase (BTK) degrader, BGB-16673, for the ...
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...
DPA International on MSN8d
EMA recommends approval of additional Alzheimer's treatment
The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.
Pharmaceutical Technology on MSN5d
Gilead wins positive European approval opinion for twice-yearly HIV injection
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...
The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.
The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in hematopoietic stem-cell transplant. About Hematopoietic stem cell transplant-associated thrombotic ...
European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback